The FDA received an application for Nubeqa as a potential treatment option with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer.

FINDINGS A study led by researchers from the UCLA Health Jonsson Comprehensive Cancer Center sheds light on testosterone ...

A new study sheds light on testosterone recovery following androgen deprivation therapy (ADT) in men undergoing radiotherapy for prostate cancer, providing key insights for optimizing patient care.

BAYRY moves ahead with the submission of an application seeking approval of darolutamide in combination with androgen ...

The ARANOTE trial confirmed radiographical PFS benefit to adding darolutamide to androgen deprivation therapy without ...

ORION CORPORATION INVESTOR NEWS 26 SEPTEMBER 2024 at 11.00 EEST Orion's collaboration partner Bayer submits application to U.S. FDA for third indication of darolutamide which has become the ...

Researchers at the Medical College of Georgia found that androgen deprivation therapy (ADT) for prostate cancer may increase Alzheimer’s risk by damaging the blood-brain barrier and promoting brain ...

A study led by researchers from the UCLA Health Jonsson Comprehensive Cancer Center sheds light on testosterone recovery ...

ESMO Congress, an expert explained how Nubeqa may reduce fatigue-related side effects in metastatic hormone-sensitive ...

German pharmaceutical company Bayer AG (BAYZF.PK, BAYRY.PK, BYR.L) announced Thursday the submission of a supplemental new drug ...

Bayer is targeting a broader use of Nubeqa in metastatic hormone-sensitive prostate (mHSPC) cancer with a combination free of ...